XML 30 R20.htm IDEA: XBRL DOCUMENT v3.22.0.1
Note 12 - Segment Information
 9 Months Ended
Dec. 31, 2021
Notes to Financial Statements  
Segment Reporting Disclosure [Text Block]

Note 12. Segment Information

 

Following the Agena Acquisition discussed in Note 11. "Significant Transactions," we realigned our financial reporting segments to reflect how management evaluates the business and allocates resources. The acquisition of Agena expanded our presence further into the life sciences tools market and provided an impetus for the creation of our new Clinical Genomics reportable segment. The strategic shift in our business also resulted in a change to the way we manage other business units, and as a result, our historical Instruments and Continuous Monitoring reportable segments have been combined to create Calibration Solutions. Prior year amounts presented have been reclassified to conform to current year presentation. Our change in financial reporting segments has not resulted in any change to previously reported consolidated amounts.

 

  

Three Months Ended December 31,

  

Nine Months Ended December 31,

 
  

2021

  

2020

  

2021

  

2020

 

Revenues:

                

Sterilization and Disinfection Control

 $13,831  $13,077  $43,014  $37,696 

Biopharmaceutical Development

  12,756   8,711   32,188   23,791 

Calibration Solutions

  11,624   12,384   33,769   34,486 

Clinical Genomics

  16,485   -   16,485   - 

Total revenues (a)

 $54,696  $34,172  $125,456  $95,973 
                 

Gross profit (loss)

                

Sterilization and Disinfection Control

 $9,945  $9,308  $31,859  $28,098 

Biopharmaceutical Development

  8,768   4,616   20,061   15,294 

Calibration Solutions

  6,090   6,869   18,330   18,962 

Clinical Genomics

  3,924   -   3,924   - 

Reportable segment gross profit

  28,727   20,793   74,174   62,354 

Corporate and Other (b)

  (100)  (140)  (196)  (76)

Gross profit

 $28,627  $20,653  $73,978  $62,278 

Reconciling Items:

                

Operating expenses

  31,139   20,631   69,166   54,216 

Operating (loss) income

  (2,512)  22   4,812   8,062 

Nonoperating (income) expense, net

  (171)  5,749   1,192   10,651 

(Loss) earnings before income taxes

 $(2,341) $(5,727) $3,620  $(2,589)

 

 

(a)

Intersegment revenues are not significant and are eliminated to arrive at consolidated totals.

 

(b)

Non-reportable operating segments and unallocated corporate expenses are reported within Corporate and Other. 

 

The following table sets forth inventories by reportable segment. Our chief operating decision maker is not provided with any other segment asset information.

  

December 31,

  

March 31,

 
  

2021

  

2021

 

Sterilization and Disinfection Control

 $2,146  $2,333 

Biopharmaceutical Development

  4,482   4,162 

Calibration Solutions

  5,531   4,683 

Clinical Genomics

  11,560   - 

Total inventories

 $23,719  $11,178